Study ID: TV48125-CNS-30051 | 2015-004550-18
Study Title
- Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Teva Identifier
- TV48125-CNS-30051 | 2015-004550-18
ClinicalTrials.gov Identifier
- NCT02638103
Study Status
- Completed
Trial Condition(s)
- Migraine
Interventions
- Drug: Fremanezumab | Drug: Placebo
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial

Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 70 Years
Trial Duration
- February 26, 2016 - December 8, 2018
Phase
- Phase 3
Study Type
Interventional